Paul D Rubin sold $157k of BIOA
Chief Medical Officer at BioAge Labs, Inc.. 8,820 shares at an average of $17.81, traded Apr 1, 2026, filed Apr 3, 2026.
Score components
- +15RoleOfficer
- +11Trade size$157k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.2%, 3m +43.2%, 6m -62.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001210905-26-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | MOption exercise Common Stock10b5-1 | +5,437 | $4.11 | $22k | 5,437 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Common Stock10b5-1 | +3,383 | $6.57 | $22k | 8,820 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -8,820 | $17.81 | $157k | 0 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,437 | $0.00 | $0 | 0 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,383 | $0.00 | $0 | 0 | Apr 3, 2026 |
Related signals
Other insiders at BioAge Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $1.6M 62,566 shares | -148% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $151k 7,433 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $139k 7,433 shares | -100% | |
| 40Moderate | BioAge Labs, Inc. | Dov A Goldstein Md Chief Financial Officer | $532k 27,000 shares | -55% | |
| 50Moderate | BioAge Labs, Inc. | Kristen Fortney Chief Executive Officer | $4.2M 233,107 shares | -19% | |
| 25Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $95k 7,433 shares | -100% | |
| 12Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $216k 18,000 shares | -100% | |
| 21Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $702k 68,897 shares | -100% | |
| 44Moderate | BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $47k 2,632 shares | - | |
| 66Notable | BioAge Labs, Inc. | Vijay Satyanand Pande director | $4.3M 219,195 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.